NCT01494857View on ClinicalTrials.gov

Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis

PHASE3UnknownINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Ulcerative Colitis
Interventions
DRUG

Adalimumab

Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.

Trial Locations (3)

Unknown

NOT_YET_RECRUITING

Sherutey Briuth Clalit / Clalit HMO, Herzlyia

RECRUITING

Lev Talpiot Clinic, Clalit health Services, Jerusalem

RECRUITING

Zevulun Clinic, Clalit Health Services, Kiryat Bialik

Sponsors
All Listed Sponsors
lead

Clalit Health Services

OTHER

NCT01494857 - Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis | Biotech Hunter | Biotech Hunter